Verzenio (Abemaciclib) 150 mg Tablets

How it Works

Verzenio (abemaciclib) is a targeted therapy used in the treatment of certain types of breast cancer. It works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6). These kinases are enzymes that, when overactive, contribute to the proliferation of cancer cells. By inhibiting CDK4/6, Verzenio interferes with the cell cycle, specifically preventing the transition from the G1 phase to the S phase, which is crucial for cell division. This results in the slowing down or stopping of cancer cell growth and replication, thereby controlling the progression of the disease.

Side Effects

• Diarrhea
• Neutropenia (low white blood cell count)
• Nausea
• Fatigue
• Abdominal pain
• Infections
• Low red blood cell count (anemia)
• Decreased appetite
• Vomiting
• Headache
• Hair thinning or loss
• Thrombocytopenia (low platelet count)
• Increased liver enzymes

Indications

• Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer
• In combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women
• In combination with fulvestrant in patients with disease progression following endocrine therapy
• As monotherapy for adult patients with HR+, HER2- advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting

Contraindications

• Hypersensitivity to abemaciclib or any of its excipients
• Severe hepatic impairment
• Pregnancy and breastfeeding (use with caution and only if clearly needed)
• Concurrent use with strong CYP3A inhibitors

Price Comparison in Different Countries

Country	Price (USD)	Website
United States	$13,000	GoodRx
Canada	$11,000	PharmacyChecker
United Kingdom	?10,000	NHS
Australia	AUD 15,000	PBS
India	?950,000	Medindia

Top 5 Global Brands

1. Verzenio (Eli Lilly and Company)
2. Ibrance (Pfizer)
3. Kisqali (Novartis)
4. Tykerb (GlaxoSmithKline)
5. Arimidex (AstraZeneca)